This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Taisho Pharmaceutical Co., Ltd.
Drug Names(s): GPCR Drug
Description: The drug candidate is a novel oral compound. Arena and Taisho's G protein-coupled receptor (GPCR)-focused collaboration was directed toward identification studies for a receptor of interest to Taisho. Although the endogenous ligand for the unknown receptor has been previously identified, the name of the endogenous ligand has not been revealed.
Deal Structure: Under an amended agreement with Taisho, which was initially executed in May of 2000 to research a number of different GPCR targets of interest to Taisho, Taisho is responsible for development and commercialization of the drug candidate. Arena is entitled to a low single digit royalty on any product revenues received by Taisho from the sale of the drug candidate. If Taisho out-licenses the drug candidate, Arena is entitled to receive additional payments after Taisho recovers expenses associated with the research and development of the GPCR-focused projects. Arena is not entitled to any further milestone payments under the partnership.
Partners: Arena Pharmaceuticals, Inc.
GPCR Drug News
Additional information available to subscribers only: